Early life treatment with vancomycin reduces diabetes incidence in NOD mice

Camilla Hartmann Friis Hansen; Dennis Sandris Nielsen; Finn Kvist Vogensen; Axel Jacob Kornerup Hansen

Early life treatment with vancomycin reduces diabetes incidence in NOD mice

Camilla Hartmann Friis Hansen, Dennis Sandris Nielsen, Finn Kvist Vogensen, Axel Jacob Kornerup Hansen

Abstract

Type 1 diabetes (T1D) results from an uncontrolled T cell mediated destruction of the insulin-producing beta-cells in the pancreas. Causal factors include a combination of genetics, early life incidents and the food we eat. The involved adaptive immune response can be down regulated by a regulatory immune response and a fine-tuned balance between these immunological components is crucial for characteristics of the disease, such as severity, onset time and recovery.
The balance between the regulatory and the adaptive immune response is heavily influenced by early life bacterial stimulation. An interplay that is likely to represent a critical environmental component to diabetes induction. In a period after birth alterations of the early microbial colonization of the gut therefore can be expected to have an immense impact on diabetes progression later in life.
In this study neonate NOD mice were treated with the antibiotic vancomycin in four weeks from birth. Diabetes incidence and onset time were compared with a control group and we found that neonate vancomycin treatment attenuates T1D. By changing the gut flora composition in the beginning of life we also demonstrated a disruption of the mechanisms regulating intestinal immune homeostasis toward a proinflammatory mucosal environment.

Original language	English
Publication date	Apr 2011
Publication status	Published - Apr 2011
Event	Mucosal Immunology and Health and Disease - San Fransisco, United States Duration: 14 Apr 2011 → 16 Apr 2011

Conference

Conference	Mucosal Immunology and Health and Disease
Country/Territory	United States
City	San Fransisco
Period	14/04/2011 → 16/04/2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@conference{aab869c783d740a8907cf2066d26a88c,

title = "Early life treatment with vancomycin reduces diabetes incidence in NOD mice",

abstract = "Type 1 diabetes (T1D) results from an uncontrolled T cell mediated destruction of the insulin-producing beta-cells in the pancreas. Causal factors include a combination of genetics, early life incidents and the food we eat. The involved adaptive immune response can be down regulated by a regulatory immune response and a fine-tuned balance between these immunological components is crucial for characteristics of the disease, such as severity, onset time and recovery. The balance between the regulatory and the adaptive immune response is heavily influenced by early life bacterial stimulation. An interplay that is likely to represent a critical environmental component to diabetes induction. In a period after birth alterations of the early microbial colonization of the gut therefore can be expected to have an immense impact on diabetes progression later in life. In this study neonate NOD mice were treated with the antibiotic vancomycin in four weeks from birth. Diabetes incidence and onset time were compared with a control group and we found that neonate vancomycin treatment attenuates T1D. By changing the gut flora composition in the beginning of life we also demonstrated a disruption of the mechanisms regulating intestinal immune homeostasis toward a proinflammatory mucosal environment. ",

author = "Hansen, {Camilla Hartmann Friis} and Nielsen, {Dennis Sandris} and Vogensen, {Finn Kvist} and Hansen, {Axel Jacob Kornerup}",

year = "2011",

month = apr,

language = "English",

note = "Mucosal Immunology and Health and Disease ; Conference date: 14-04-2011 Through 16-04-2011",

}

TY - CONF

T1 - Early life treatment with vancomycin reduces diabetes incidence in NOD mice

AU - Hansen, Camilla Hartmann Friis

AU - Nielsen, Dennis Sandris

AU - Vogensen, Finn Kvist

AU - Hansen, Axel Jacob Kornerup

PY - 2011/4

Y1 - 2011/4

N2 - Type 1 diabetes (T1D) results from an uncontrolled T cell mediated destruction of the insulin-producing beta-cells in the pancreas. Causal factors include a combination of genetics, early life incidents and the food we eat. The involved adaptive immune response can be down regulated by a regulatory immune response and a fine-tuned balance between these immunological components is crucial for characteristics of the disease, such as severity, onset time and recovery. The balance between the regulatory and the adaptive immune response is heavily influenced by early life bacterial stimulation. An interplay that is likely to represent a critical environmental component to diabetes induction. In a period after birth alterations of the early microbial colonization of the gut therefore can be expected to have an immense impact on diabetes progression later in life. In this study neonate NOD mice were treated with the antibiotic vancomycin in four weeks from birth. Diabetes incidence and onset time were compared with a control group and we found that neonate vancomycin treatment attenuates T1D. By changing the gut flora composition in the beginning of life we also demonstrated a disruption of the mechanisms regulating intestinal immune homeostasis toward a proinflammatory mucosal environment.

AB - Type 1 diabetes (T1D) results from an uncontrolled T cell mediated destruction of the insulin-producing beta-cells in the pancreas. Causal factors include a combination of genetics, early life incidents and the food we eat. The involved adaptive immune response can be down regulated by a regulatory immune response and a fine-tuned balance between these immunological components is crucial for characteristics of the disease, such as severity, onset time and recovery. The balance between the regulatory and the adaptive immune response is heavily influenced by early life bacterial stimulation. An interplay that is likely to represent a critical environmental component to diabetes induction. In a period after birth alterations of the early microbial colonization of the gut therefore can be expected to have an immense impact on diabetes progression later in life. In this study neonate NOD mice were treated with the antibiotic vancomycin in four weeks from birth. Diabetes incidence and onset time were compared with a control group and we found that neonate vancomycin treatment attenuates T1D. By changing the gut flora composition in the beginning of life we also demonstrated a disruption of the mechanisms regulating intestinal immune homeostasis toward a proinflammatory mucosal environment.

M3 - Poster

T2 - Mucosal Immunology and Health and Disease

Y2 - 14 April 2011 through 16 April 2011

ER -